HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a pharmaceutical company specializing in treatments for tumors and viruses, has initiated the exercise of existing warrants which is expected to ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Kingsview Wealth Management LLC lifted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 60.3% during the ...

“If small biotech companies like ours are forced to scale back or shut down, it will not just be a loss for scientific ...

Donald Trump Jr. and Eric Trump are participating in Dominari Holdings' private placement and are joining its advisory board.

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

Maxim downgraded Moleculin Biotech (MBRX) to Hold from Buy.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...